JAK2 and pulmonary arterial hypertension: Other studies reported that administration of JAK2 specific inhibitors, such as TG-101344 (also named Fedratinib) (Zhang et al., 2020) or JSI-124 (Milara et al., 2018), can delay the progression of PAH by inhibiting the activation of the JAK2/STAT3 pathway.